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Introduction: It has previously been shown that an increased number of antibodies against citrullinated peptides/
proteins (ACPA) predate the onset of rheumatoid arthritis (RA). Over time antibody positivity expands, involving more
specific responses when approaching the onset of symptoms. We investigated the impact of human leukocyte
antigen-shared epitope (HLA-SE) alleles and smoking on the development of ACPA, as well as in combination with
ACPA during the state of quiescent autoimmunity (before the onset of symptoms), on the development of RA.
Methods: Blood samples donated to the Medical Biobank of Northern Sweden from individuals prior to the onset of
symptoms of RA (n = 370) and after onset (n = 203) and from population-based controls (n = 585) were used.
Antibodies against 10 citrullinated peptides, fibrinogen (Fibα561-583, α580-600, ß62-81a, ß62-81b, ß36-52), vimentin
(Vim2-17, 60-75), filaggrin (CCP-1/Fil307-324), α-enolase (CEP-1/Eno5-21), collagen type II (citC1359-369), and anti-cyclic
citrullinated peptide (CCP)2 antibodies were analysed.
Results: HLA-SE-positive individuals were more frequently positive for ACPA compared with HLA-SE-negative individuals
prior to the onset of symptoms of RA, particularly for antibodies against CEP-1 and Fibß62-81a (72). Smoking was
associated with antibodies against Vim2-17 and citC1359-369. HLA-SE and smoking showed increasing association to
the presence of the antibodies closer to disease onset. The highest odds ratio (OR) for development of RA was for the
combination of HLA-SE alleles and ACPA positivity, especially for antibodies against Fibß62-81b, CCP-1/Fil307-324,
and Fibβ36-52. A gene-environment additive interaction between smoking and HLA-SE alleles for the risk of
disease development was found, with the highest OR for individuals positive for antibodies against Fibβ36-52,
CEP-1, and Fibα580-600.
Conclusions: The relationships between antibodies against the different ACPA specificities, HLA-SE, and smoking
showed a variable pattern in individuals prior to the onset of RA. The combination of smoking and HLA-SE alleles was
significantly associated with the development of some of the antibody specificities closer to onset of symptoms, and
these associations remained significant at diagnosis. An additive gene-environment interaction was found for several
of the antibodies for the development of RA.* Correspondence: solbritt.rantapaa.dahlqvist@umu.se
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Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by joint inflammation that eventually
leads to the destruction of cartilage and bone. The aetio-
pathogenesis of the disease is not yet fully understood. It
has previously been shown that the presence of anti-
bodies against citrullinated proteins/peptides (ACPA),
analysed as anti-cyclic citrullinated peptide (CCP) anti-
bodies of immunoglobulin (Ig)G, IgA, and IgM isotypes,
precedes the development of RA by several years [1-4].
More recently, we have also shown that an increased
number of ACPA antibody specificities predate the onset
of RA [5]. These ACPA antibody specificities were initially
restricted and without any obvious epitope profile, but
over time they expanded and involved more specific re-
sponses, especially antibodies against α-enolase (CEP-1/
Eno5-21), fibrinogen (Fib)β36-52, and filaggrin (CCP-1/
Fil307-324), when approaching the onset of symptoms [5].
The strongest genetic associations with RA known to
date, HLA-shared epitope (SE) alleles and the protein
tyrosine phosphatase non receptor type 22 (PTPN22)
1858C/T polymorphism, have been shown to be confined
to ACPA-positive disease [6-8]. Recently, a study by
Lundberg et al. showed that HLA-SE, PTPN22 1858T, and
smoking were associated with specific ACPA reactivities,
especially with antibodies against CEP-1 and citrullinated
vimentin (anti-Vim 60-75) in patients with RA [9].
Additionally, in a study on Spanish RA patients, those
with anti-CEP-1 antibodies showed an interaction with
PTPN22 1858T and HLA-SE whilst having anti-cit-
vimentin antibodies was associated with the presence
of two HLA-SE alleles [10].
A recent study of genetic and environmental determi-
nants for the development of ACPA in healthy twins as
well as in twins with RA, demonstrated that smoking as
well as HLA-SE alleles also influenced the development
of ACPA in individuals without RA, although the impact
of HLA-SE was less pronounced as risk factor for ACPA
itself than for ACPA-positive RA [11]. The presence of re-
activities against four different ACPA was associated with
smoking and HLA-SE [11]. However, the role of the gen-
etic factors, as well as of smoking, in the development of
different ACPA specificities in individuals who have not
yet developed RA, but will subsequently do so, have not
yet been fully elucidated.
Interactions between a history of smoking and HLA-SE in
the risk for seropositive RA has been demonstrated in sev-
eral previous reports in early RA, the first one in 2006 [7], A
modest additive interaction between a history of smoking
and HLA-SE in the risk for development of seropositive RA
was shown in analyses from the Nurses’ Health Study by
Karlson et al. [12]. A strong additive interaction, as well as a
significant multiplicative interaction, was found between the
magnitude of past smoking and any HLA-SE alleles in therisk of seropositive RA [12]. In a continuation of that study,
presence of multiple ACPA reactivities and of HLA-SE
showed the highest risk for RA compared with ACPA-
negative/HLA-SE-negative individuals as reference [13].
In the present study we aimed firstly to investigate the
impact of HLA-SE alleles and smoking on the develop-
ment of several ACPA specificities during the state of
quiescent autoimmunity, that is, before the onset of symp-
toms, in individuals who all were known to later develop
RA. Secondly we aimed to investigate the importance of
these factors, independently and in combinations, in the
development of RA. We have used blood samples donated
to the Medical Biobank of Northern Sweden by these indi-
viduals prior to the onset of symptoms of RA and controls
derived from the same population.
Methods
A case-control study was conducted based on individ-
uals included within the Medical Biobank of Northern
Sweden and the Maternity cohort. The criteria for re-
cruitment, collection, and storage of blood samples have
been described previously [1].
The registers from the Medical Biobank and the
Maternity cohort were co-analysed with the registers of
patients with RA fulfilling the 1987 American Rheuma-
tism Association classification criteria for RA [14], at-
tending the Department of Rheumatology, University
Hospital in Umeå, to identify individuals who had do-
nated blood samples prior to onset of symptoms of RA.
The number of individuals identified and the procedure
for excluding any sample has previously been described
in detail [5]. Originally, 386 individuals with a total of
717 plasma samples were identified as donors and were
included in this study (71 men and 315 women, who were
referred to as ‘pre-symptomatic individuals’). Of them, 370
individuals also had DNA available. In the present ana-
lyses, we used the sample from each individual that was
the first that was positive for ACPA or anti-CCP2, respect-
ively, if not presented differently. The median (IQR) time
predating onset of symptoms was 4.6 (2.0 to 9.7) years.
Controls (N = 1307) were randomly identified from the
same cohorts within the register at the Medical Biobank
and matched for age, sex, and date of sampling. Of these
control subjects, 585 were randomly selected for geno-
typing and were included in this study. Of the pre-
symptomatic individuals, 203 were also sampled when
they were diagnosed with RA at the early arthritis clinic
(median 7.2 months (IQR: 4.7 to 10.6 months) after
symptom onset).
All individuals were classified either as a ‘non-smoker’
or an ‘ever-smoker’ (past or current). The Regional Ethics
Committee at the University Hospital, Umeå, Sweden,
approved this study, (Dnr 2011-168-31M) and all partici-
pants gave their written informed consent when donating
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individuals and controls are presented in Table 1.
After the disease had developed and the individuals were
diagnosed with RA, the frequency of antibodies against
CCP2 was 75.2% using the anti-CCP2 test (see below).Multiplex assay
Samples were analysed for antibodies against the follow-
ing 10 different citrullinated antigens: fibrinogen (Fib)
α563-583, Fibα580-600, Fibβ62-81a (72), Fibβ62-81b
(74), Fibβ36-52, α-Enolase (CEP-1/Eno5-21), triple hel-
ical collagen type II peptide containing the triple helical
aa 359-369 with two citrulline residues (citC1359-369)
[15], filaggrin (CCP-1/Fil307-324), vimentin (Vim) 2-17,
and Vim60-75 using a custom-made microarray based
on the ImmunoCAP ISAC® system (Phadia AB, Uppsala,
Sweden), as previously described [5,16]. The difference
in fluorescence intensity between the citrullinated pep-
tide and the arginine-containing peptide was calculated
and the resulting delta value was used. The exception
was the citC1359-369 peptide, for which the uncorrected
values were used [5,16]. The cutoff values for each anti-
body was set at the optimal level of sensitivity and specifi-
city, calculated using receiver operator characteristic
(ROC) curves as previously described [5]. A cutoff value
for each of the antibodies was also tested at 97%, yielding
similar frequencies of the antibodies as the ROC curves.Table 1 Demographic data for individuals with samples at a m




Median age, years 49.9
(Q1-Q3) g (30.6–58.8)
Ever-smoker (%) 230/348 (66.1)***
HLA-DR SEb, n (%) 240/366 (65.6) ***
anti-CCP2 absc, % (95% CI) 34.9 (30.2–39.9)***
anti-CEP-1/Eno5-21 abs, % (95% CI) 28.9 (24.5–33.7)***
anti-citC1359-369 abs, % (95% CI) 13.1 (10–17.1)***
anti-Fibα563-583 abs, % (95% CI) 10.8 (8–14.4)***
anti-Fibα580-600 abs, % (95% CI) 8.7 (6.2–12.1)
anti-Fibß36-52 abs, % (95% CI) 29.7 (25.3–34.6)***
anti-Fibß62-81a (72) abs, % (95% CI) 11.6 (8.7–15.3)***
anti-Fibß62-81b (74) abs, % (95% CI) 15.9 (12.5–20.1)***
anti-CCP-1/Fil307-324 abs, % (95% CI) 26.2 (22–30.9)***
anti-Vim60-75 abs, % (95% CI) 13.0 (9.9–16.8)***
anti-Vim2-17 abs, % (95% CI) 7.0 (4.8–10.2)*
*P <0.05, ***P <0.001 pre-symptomatic individuals or RA patients, respectively comp
aThe sensitivity and specificity calculations are based on ROC curves performed originally
epitope defined as 0101/0401/0404/0405/0408/. cabs = antibodies. davailable number ofAnti-CCP2 antibodies and HLA-SE alleles
Anti-CCP2 antibodies were detected using enzyme-linked
immunosorbent assay (ELISA) according to the manufac-
turer’s instructions (Euro-Diagnostica AB, Malmö, Sweden).
The cutoff level for positivity was set at 25 AU/mL. HLA-
DRB1 0101/0401/0404/0405/0408 (SE alleles) were geno-
typed as described previously [17,18] (data presented in
Table 1).
Statistics
The chi-squared test, or Fisher’s exact test when appropri-
ate, was used for testing categorical data (positive versus
negative) between groups. Simple and multiple logistic re-
gression analyses were performed to identify factors of im-
portance for the development of antibodies against various
citrullinated peptides and for the development of RA, and
the risks are presented as odds ratios (OR) with 95% confi-
dence intervals (CI). All P values are two-sided, and P
values ≤0.05 are considered to be statistically significant.
Statistical calculations were performed using SPSS for Win-
dows version 20.0 (IBM SPSS, IBM Corp, NY, USA).
Analyses of interactions were tested for using the
standard methods outlined in the article by Zou to cal-
culate the attributable proportion (AP) due to inter-
action, the relative excess risk due to interaction (RERI),
and the synergy index (SI) [19]. For models in which the
variable HLA-SE was stratified into three categories (0,
1, or 2 HLA-SE alleles present), the additive interactionedian of 4.6 years (Q1 to Q3: 2.0 to 9.7) before the onset
ndividuals) at diagnosis and controls
viduals RA Controlsa




136/200 (68)*** 254/552 (46.0)
129/204 (63.2) *** 229/585 (39.1)
74.5 (68.0–80.0)***d 2.4 (1.4–4.0)
67.3 (60.5–73.5)***e 6.1 (4.4–8.4)f
32.2 (26.1–39.0)***e 4.4 (3.0–6.4)f
34.2 (27.9–41.0)***e 5.2 (3.6–7.4)f
14.1 (9.9–19.7)***e 6.1 (4.4–8.4)f
64.8 (58.0–71.1)***e 6.6 (4.9–9.0)f
14.6 (10.3–20.2)***e 3.1 (2.0–5.0)f
34.2 (27.9–41.0)***e 1.7 (0.9–3.2)f
46.2 (39.4–53.2)***e 3.0 (1.8–4.7)f
29.1 (23.3–35.8)***e 5.4 (3.8–7.6)f
11.1 (7.4–16.3)***e 3.8 (2.5–5.8)f
ared with controls.
on the RA cases (n = 200/199) and controls (n = 1,307) [5]. bHLA-DR SE = shared
samples analysed = 200. en = 199. fn = 574. g (Q1-Q3)=first quartile to third quartile.
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of HLA-SE (no HLA-SE allele present). Multiplicative
interaction was assessed by adding an interaction term
(for example HLA-SE* smoking) to the regression
models. A P value <0.05 was considered as evidence for
departure from the multiplicative model of association.
All the interactions were calculated using the statistical
software R (R core team) [20].
Results
Impact of HLA-SE and smoking on the presence of different
ACPA-fine specificities prior to the onset of symptoms and
at diagnosis of rheumatoid arthritis
The presence of HLA-SE (defined as 0101/0401/0404/
0405/0408) predicted positivity of antibodies against
Fibß62-81a (72) (OR = 2.52, 95% CI: 1.13 to 5.61),
and of CEP-1 (OR = 1.65, 95% CI: 1.003 to 2.73),
including all pre-dating samples in the analyses (data
not shown). Being homozygous for HLA-SE gave a
higher OR for having antibodies against Fibß62-81b (74)
(OR = 3.82, 95% CI: 1.57 to 9.32), Fibß62-81a (72) (OR =
3.24, 95% CI: 1.05 to 10.2), and CCP2 (OR = 2.41, 95%
CI: 1.14 to 5.09) compared with being SE-allele-negative
(data not shown). Individuals with HLA-SE had signifi-
cantly more ACPA specificities, with a median number of
antibodies of 1 (IQR: 3) compared with 0 (IQR: 1) for
those who were HLA-SE negative, (P <0.01, data not
shown). The conversion from being seronegative during
the pre-symptomatic period and positive after disease on-
set was enhanced significantly by the presence of HLA-
SE (OR = 3.3, 95% CI: 1.8 to 6.1). Being an ever-smoker
among the pre-symptomatic individuals was associated
with antibodies against Vim2-17 (OR = 4.05, 95% CI: 1.18
to 13.84), citC1359-369 (OR = 2.09, 95% CI: 1.00 to 4.39),
and CCP2 (OR = 1.65, 95% CI: 1.02 to 2.66). However,
smokers did not have a higher number of ACPA specific-
ities compared with non-smokers (data not shown).
When all samples from the pre-symptomatic individuals
were evaluated, the combination of HLA-SE alleles and
smoking was significantly associated with antibodies against
CCP2 and Fibβ62-81b, the reference being non-smoker
without HLA-SE alleles (Table 2). When only including
samples closer to disease onset in the analyses (when the
frequencies of the different antibodies started to increase,
≤10.5 years prior to symptom onset of RA, n = 288 individ-
uals), the presence of antibodies against CCP2, CEP-1/
Eno5-21, citC1359-369, Fibβ62-81b, Fibβ36-52, and CCP-
1/Fil307-324 were all significantly associated with the com-
bination of HLA-SE and ever-smoking (Table 2). At the
time of diagnosis, the combination of smoking and HLA-
SE alleles had significant ORs for all of these antibodies,
and additionally for Fibα561-583 and Vim60-75, with the
exception of CCP-1/Fil307-324 that was non-significant
after disease onset (Table 2).Further analyses of the association of HLA-SE alleles
with the levels of the different antibodies showed that
higher levels of antibodies (three times above the cutoff
level for each antibody) against CCP2, CEP-1/Eno5-21,
and Fibß62-81b was associated with having HLA-SE al-
leles (P <0.05 for all, data not shown).
Impact of HLA-SE, smoking, and individual ACPA prior to
onset of symptoms on the risk of development of
rheumatoid arthritis
All ACPA analysed, except anti-Fibα580-600, predicted
the development of RA (Table 3). Adjustment of the
data for smoking and HLA-SE did not affect the calcu-
lated risk of the antibodies, except that anti-Vim2-17
antibodies became non-significant when adjusted for
smoking (Table 3).
In the pre-symptomatic individuals HLA-SE, and par-
ticularly HLA-SE homozygosity was associated with sub-
sequent development of RA (OR = 2.96, 95% CI: 2.26 to
3.89 and OR = 5.47, 95% CI: 3.05 to 9.83, respectively).
Ever smoking was similarly associated with disease devel-
opment (OR = 2.29, 95% CI: 1.73 to 3.02; data not shown).
Relationship of HLA-SE alleles and ACPA reactivities in
development of rheumatoid arthritis
The highest risk for development of RA was to be posi-
tive for the combination of HLA-SE and ACPA, using
individuals lacking both HLA-SE and ACPA as refer-
ence. The highest OR was found for the combinations of
HLA-SE alleles and antibodies against CCP2, Fibβ62-
81b, CCP-1/Fil307-324, CEP-1/Eno5-21, and Fibß36-52
(Figure 1). It is also evident that the impact of the presence
of HLA-SE varies strongly between the different antibodies.
This analysis was also performed in the ACPA-positive sub-
group (including cases and controls positive for any ACPA
reactivity), to exclude the possibility that the interactions
are explained simply by ACPA status, and yielded similar
results.
Combinations of separate or several ACPA with smoking
and HLA-SE alleles on the risk of development of
rheumatoid arthritis
Individuals were distributed into subgroups based on the
presence or absence of ever smoking, and carriage of
HLA-SE alleles and of individual ACPA or ACPA combi-
nations, with the reference groups comprising of ACPA-
negative non-smokers without HLA-SE. The combinations
of being a smoker and having HLA-SE together with any of
the four most frequently occurring antibodies, (CEP-1/
Eno5-21, Fibß36-52, CCP-1/Fil307-324, and CCP2) yielded
very high ORs in relation to HLA-SE- and ACPA-negative
non-smokers, although these combinations of triplets com-
prised relatively low numbers of individuals (presented in
Table 4). The combination of three (CEP-1/Eno5-21,
Table 2 Odds ratio for disease development of anti-CCP2 antibodies and different ACPA prior to symptoms of RA (pre-RA),
≤10.5 years prior to symptoms, and at diagnosis in combination with HLA-SE allele (none/any), smoking (never/ever)
Pre-RA (ever-pos) Pre-RA (≤10.5 years) RA
(n = 348) (n = 277) (n = 196)
HLA-SE Smoking OR (95% CI) OR (95% CI) OR (95% CI)
Anti-CCP2
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.36 (0.57–3.22) 1.81 (0.81–4.00) 1.06 (0.36–3.14)
None Ever 1.50 (0.64–3.53) 1.41 (0.62–3.22) 1.02 (0.36–2.88)
Any Ever 2.36 (1.08–5.17) 3.96 (1.87–8.39) 4.23 (1.42–12.59)
Anti-CEP-1/Eno5-21
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.40 (0.56–3.55) 1.08 (0.46–2.55) 1.44 (0.51–4.03)
None Ever 1.38 (0.55–3.48) 1.38 (0.59–3.27) 1.92 (0.70–5.26)
Any Ever 2.25 (0.97–5.23) 2.85 (1.30–6.24) 6.59 (2.42–17.99)
Anti-CitC1359-369
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.20 (0.29–4.92) 1.74 (0.47–6.54) 3.88 (0.44–34.48)
None Ever 2.00 (0.52–7.64) 2.28 (0.61–8.47) 14.93 (1.85–120.33)
Any Ever 2.59 (0.74–9.07) 4.05 (1.19–13.82) 14.67 (1.89–113.98)
Anti-Fibα580-600 (591)
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.31 (0.38–4.47) 1.57 (0.41–5.96) 0.17 (0.02–1.75)
None Ever 0.61 (0.15–2.40) 0.88 (0.20–3.83) 1.37 (0.33–5.73)
Any Ever 0.69 (0.20–2.26) 1.39 (0.38–5.07) 1.32 (0.34–5.03)
Anti-Fibα563-583 (573)
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.61 (0.31–8.34) 1.89 (0.39–9.21) 2.22 (0.54–9.09)
None Ever 2.79 (0.58–13.42) 3.16 (0.67–14.84) 3.13 (0.80–12.17)
Any Ever 3.09 (0.69–13.79) 3.42 (0.77–15.17) 5.14 (1.42–18.61)
Anti-Fibβ62-81a (72)
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 4.98 (1.09–22.90) 4.90 (0.61–39.36) 2.44 (0.26–23.30)
None Ever 1.58 (0.31–8.23) 3.33 (0.39–28.40) 1.50 (0.15–15.27)
Any Ever 2.76 (0.61–12.36) 6.99 (0.91–53.38) 5.91 (0.75–46.86)
Anti-Fibβ62-81b (74)
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 2.00 (0.52–7.64) 7.14 (0.91–55.83) 2.53 (0.63–10.23)
None Ever 2.00 (0.52–7.64) 6.45 (0.81–51.41) 2.55 (0.65–10.05)
Any Ever 3.52 (1.02–12.20) 16.73 (2.24–124.88) 5.93 (1.64–21.44)
Anti-Fibβ36-52
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.20 (0.50–2.86) 1.45 (0.58–3.67) 0.85 (0.30–2.39)
None Ever 1.18 (0.49–2.81) 1.65 (0.65–4.20) 0.80 (0.29–2.19)
Any Ever 1.64 (0.74–3.61) 3.64 (1.54–8.57) 3.08 (1.15–8.21)
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Table 2 Odds ratio for disease development of anti-CCP2 antibodies and different ACPA prior to symptoms of RA (pre-RA),
≤10.5 years prior to symptoms, and at diagnosis in combination with HLA-SE allele (none/any), smoking (never/ever)
(Continued)
Anti-CCP-1/Fil307-324
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.81 (0.73–4.51) 3.67 (1.34–10.06) 0.66 (0.23–1.85)
None Ever 1.20 (0.47–3.06) 1.97 (0.68–5.69) 0.51 (0.18–1.42)
Any Ever 1.77 (0.76–4–14) 4.05 (1.52–10.79) 1.42 (0.56–3.56)
Anti-Vim60−75
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.42 (0.47–4.32) 6.56 (0.84–51.59) 2.53 (0.63–10.23)
None Ever 0.58 (0.17–2.04) 2.74 (0.31–24.11) 1.17 (0.27–5.00)
Any Ever 1.02 (0.35–2.91) 6.20 (0.81–47.64) 4.67 (1.29–16.92)
Anti-Vim2-17
None Never 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any Never 1.04 (0.09–11.83) 2.34 (0.27–20.54) 1.41 (0.33–6.10)
None Ever 2.67 (0.30–23.68) 2.17 (0.24–19.94) 0.62 (0.13–3.04)
Any Ever 4.99 (0.64–38.65) 6.20 (0.81–47.64) 0.69 (0.17–2.85)
Significant associations presented in bold. HLA-SE= HLA shared epitope, OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide
antibodies, anti CEP-1/Eno5-21= antibodies against α-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues,
anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against
Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against
filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.
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Eno5-21, Fibß36-52, and CCP-1/Fil307-324) of the most
frequently occurring antibodies being positive together with
smoking and HLA-SE resulted in even higher ORs for de-
velopment of RA among the pre-symptomatic individuals
(OR = 61.03, 95% CI: 13.95 to 267.05), compared withTable 3 Risk for development of RA in individuals before the
Antibodies Frequency OR (95% CI)
N (%)
Anti-CCP2 129 (34.9) 21.83 (12.33–38.6
Anti-CEP-1/Eno5-21 107 (28.9) 6.27 (4.16–9.43)
Anti-CitC1359-369 47 (13.1) 3.32 (2.00–5.50)
Anti-Fibα580-600 (591) 31 (8.7) 1.46 (0.88–2.41)
Anti-Fibα563-583 (573) 40 (10.8) 2.20 (1.34–3.60)
Anti-Fibβ62-81a (72) 43 (11.6) 4.06 (2.30–7.16)
Anti-Fibβ62-81b (74) 57 (15.9) 10.68 (5.38–21.22
Anti-Fibβ36-52 110 (29.7) 5.97 (4.01–8.88)
Anti-CCP-1/Fil307-324 97 (26.2) 11.64 (6.82–19.88
Anti-Vim60-75 48 (13.0) 2.61 (1.63–4.19)
Anti-Vim2-17 29 (7.0) 1.90 (1.06–3.40)
OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide antibo
against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodi
Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)=
anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimbeing negative for any of the antibodies (Table 4). Analysing
for all four antibodies (CCP2, CEP-1/Eno5-21, Fibß36-52,
and CCP-1/Fil307-324) being positive versus all four being
negative yielded an even higher OR (Table 4). Multiple lo-
gistic regression analyses including each separate ACPA
and anti-CCP2 antibodies, HLA-SE, and smoking showedonset of any symptoms of disease (n = 370)
OR (95% CI) OR (95% CI)
Adjusted for smoking Adjusted for HLA-SE
(n = 348) (n = 366)
7) 21.69 (11.96–39.33) 19.52 (10.96–34.79)
5.69 (3.74–8.66) 5.57 (3.67–8.46)
3.04 (1.82–5.10) 3.27 (1.94–5.50)
1.39 (0.82–2.36) 1.54 (0.91–2.61)
2.10 (1.25–3.53) 2.15 (1.29–3.57)
4.42 (2.47–7.91) 3.44 (1.92–6.17)
) 10.05 (5.02–20.10) 9.48 (4.72–19.05)
6.07 (4.00–9.22) 5.66 (3.76–8.51)
) 12.10 (6.94–21.10) 10.39 (6.03–17.90)
2.37 (1.45–3.88) 2.50 (1.54–4.08)
1.55 (0.85–2.85) 1.85 (1.01–.3.39)
dies, anti CEP-1/Eno5-21= antibodies against α-Enolase, anti-citC1359-369= antibodies
es against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against
antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52,
entin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.
Figure 1 Odds ratio (OR) for development of RA in individuals prior to the onset of RA stratified for ACPA reactivity and the presence of HLA-SE
alleles. Individuals without HLA-SE and ACPA were used as reference. HLA-SE+= HLA shared epitope present, HLA-SE-=HLA shared epitope
absent, OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide antibodies, anti CEP-1/Eno5-21= antibodies against
α- Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against
fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72),
anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against
filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.
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tors for the development of RA in all analyses (Additional
file 1: Table S1).
Gene-environment interactions in individuals, prior to
diagnosis, for risk of developing rheumatoid arthritis
An additive interaction was evident between smoking
and HLA-SE alleles regardless of ACPA status in indi-
viduals prior to the diagnosis of RA, with an AP of 0.48
(95% CI: 0.43 to 0.55) (Table 5). When stratifying the
data from individuals prior to the onset of symptoms of
RA according to having the various ACPA specificities, a
gene-environment additive interaction for development
of RA was found for seropositivity as well as seronega-
tivity; however, there was at least a doubled OR for
ACPA-fine specificity-positive individuals, with the ex-
ception of anti-Fibα580-600 and anti-Vim60-75 anti-
bodies (Table 5). There were no significant multiplicative
gene-environment interactions of HLA-SE alleles and
smoking in any of the groups for the development of RA
among individuals prior to diagnosis. Also, when analys-
ing the relationship of HLA-SE and the most frequentACPA reactivities, an additive interaction for develop-
ment of RA between HLA-SE and some of the ACPA
was significant, namely for CEP-1/Eno5-21 (AP = 0.67,
95% CI: 0.57 to 0.73) and Fibß36-52 (AP = 0.60, 95% CI:
0.49 to 0.67), as was being positive for any of the ACPA
(AP = 0.61, 95% CI: 0.58 to 0.65). No significant interac-
tions were shown for smoking together with the ACPA
reactivities or anti-CCP2 antibodies (data not shown).
There were no significant interactions for the triple com-
bination of presence of HLA-SE, smoking, and anti-CEP-
1/Eno5-21, anti-CCP-1/Fil307-324, or anti-Fibß36-52 anti-
bodies, or any ACPA separately analysed.
Discussion
In this study blood samples that had been identified
within population surveys from individuals years before
they reported any symptoms of a subsequent joint dis-
ease were included. These samples together with sam-
ples from controls were analysed for different ACPA
specificities in relation to genetic and environmental de-
terminants. This is the first study where the relation-
ships between the presence of a number of different
Table 4 Odds ratios (ORs) for disease development in pre-symptomatic individuals for different ACPA and anti-CCP2 in
combination with smoking and HLA-SE compared with individuals being ACPA/anti-CCP2 negative, HLA-SE negative,
and non-smokers as reference
Anti-CCP2/ACPA Smoking HLA-SE Cases/controls OR (95% CI)
(n = 348) (n = 366) n/n
Anti-CCP2 345/552a
− − − 31/172 Ref
+ − − 10/1 55.48 (6.86–448.99)
− + − 52/160 1.80 (1.10–2.96)
– – + 52/121 2.38 (1.44–3.94)
+ + – 26/3 48.09 (13.71–168.64)
− + + 84/86 5.42 (3.33–8.82)
+ − + 24/4 33.29 (10.80–102.59)
+ + + 66/5 73.24 (27.32–196.37)
Anti-CEP-1/Eno5-21 345/541a
− − − 33/163 Ref
+ − − 8/7 5.65 (1.92–16.64)
− + − 58/147 1.95 (1.20–3.16)
− − + 56/117 2.36 (1.45–3.86)
+ + − 20/14 7.05 (3.24–15.37)
− + + 96/79 6.00 (3.72–9.68)
+ − + 20/7 14.11 (5.52–36.08)
+ + + 54/7 38.10 (15.94–91.11)
Anti-Fibβ36-52 345/541a
− − − 31/161 Ref
+ − − 10/9 5.77 (2.17–15.36)
− + − 56/149 1.95 (1.19–3.19)
− − + 54/117 2.40 (1.45–3.96)
+ + − 22/12 9.52 (4.27–21.22)
− + + 97/79 6.38 (3.92–10.37)
+ − + 22/7 16.32 (6.42–41.51)
+ + + 53/7 39.32 (16.36–94.51)
Anti-CCP-1/Fil307-324 345/541a
− − − 33/168 Ref
+ − − 8/2 20.36 (4.14–100.24)
− + − 60/157 1.95 (1.21–3.14)
− − + 52/120 2.21 (1.35–3.62)
+ + − 18/4 22.91 (7.28–72.05)
− + + 104/80 6.62 (4.12–10.63)
+ − + 24/4 30.55 (9.94–93.84)
+ + + 46/6 39.03 (15.42–98.82)
Anti-CEP-1/Eno5-21 + anti-Fibβ36-52 + anti-CCP-1/Fil307-324b 345/541a
− − − 39/170 Ref
+ − − 1/0 −
− + − 72/159 1.97 (1.26–3.08)
− − + 66/123 2.33 (1.48–3.70)
+ + − 6/1 26.15 (3.06–223.50)
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Table 4 Odds ratios (ORs) for disease development in pre-symptomatic individuals for different ACPA and anti-CCP2 in
combination with smoking and HLA-SE compared with individuals being ACPA/anti-CCP2 negative, HLA-SE negative,
and non-smokers as reference (Continued)
− + + 122/85 6.26 (4.01)
+ − + 11/1 47.95 (6.01–382.46)
+ + + 28/2 61.03 (13.95–267.05)
Anti-CEP-1/Eno5-21 + anti-Fibβ36-52 + anti-CCP-1/Fil307-324 + anti-CCP2c 204/464a
− − − 20/151 Ref
+ − − 1/0 −
− + − 37/133 2.10 (1.16–3.80)
− − + 37/105 2.66 (1.46–4.84)
+ + − 5/0 −
− + + 65/72 6.82 (3.84–12.11)
+ − + 11/1 83.05 (10.17–677.91)
+ + + 28/2 105.70 (23.39–477.74)
aTotal number included in analysis. bPositive = positive for all of the three antibodies and negative = any of the antibodies negative. cPositive = all four antibodies
positive and negative = all four antibodies negative. anti-CCP2=anti-cyclic citrullinated peptide antibodies, ACPA= anti citrullinated peptide/protein antibodies,
HLA-SE= HLA shared epitope, OR= odds ratio, CI= confidence intervals, anti CEP-1/Eno5-21= antibodies against alpha-Enolase, anti-citC1359-369= antibodies
against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies
against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies
against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against
Vim 2-17.
Kokkonen et al. Arthritis Research & Therapy  (2015) 17:125 Page 9 of 15ACPA besides anti-CCP2 antibodies, and HLA-SE and
smoking have been analysed years before onset of
symptoms.
In this study we have analysed the importance of
HLA-SE and smoking for the development of ACPA and
of the combination of these three risk factors for disease
development. From this study we can conclude that the
contribution of HLA-SE alleles and smoking prior to RA
increased closer to disease onset and were moderate, but
in combination with the most prevalent antibodies
(CEP-1/Eno5-21, Fibß36-52, and CCP-1/Fil307-324)
aside from anti-CCP2 antibodies, the relative risk for
disease development was highly increased. We also
found that the relationships between HLA-SE, smoking,
and the different ACPA specificities showed variable pat-
terns in individuals before they had developed symptoms
of RA. Furthermore the presence of HLA-SE and smok-
ing were independent from ACPA and anti-CCP2 anti-
bodies as risk factors for disease development.
Overall, the conclusions are that in individuals who
will subsequently develop RA, HLA-DRB1* SE alleles
and smoking were associated with the development and
increase of specific ACPA reactivities, although to a vari-
able extent. The presence of various ACPA specificities
and of anti-CCP2 antibodies was, to a moderate degree,
associated with having HLA-SE and/or being an ever-
smoker. These relationships are not as evident as has
been shown in patients with manifest RA [6,7], probably
as a result of lower frequencies of the various antibodies
before disease onset compared with after the disease has
developed. The frequencies of several of the differentACPA gradually increased as the disease developed (the
closer to onset of RA that the blood was sampled) as
previously shown [5], whilst obviously being HLA-SE
allele-positive or an ever-smoker gave similar results ir-
respective of time. Considering the combination of
HLA-SE and smoking with the development of the vari-
ous antibodies, we could not show that HLA-SE or
smoking alone was significant for the early development
and first appearance of many of the antibodies when all
individuals, irrespective of pre-dating time, were in-
cluded. However, when including only samples ≤10.5
years prior to symptom onset of RA (when the concen-
tration and frequencies of certain antibodies were in-
creasing), the combination of smoking and HLA-SE was
significantly associated with antibodies against several of
the citrullinated peptides. Furthermore, most remained
significant at diagnosis, such as antibodies against CCP2,
CEP-1/Eno5-21, citC1359-369, Fibß62-81b, and Fibß36-
52. The effect of HLA-SE alleles and smoking seemed to
be of more importance when approaching disease onset
when the frequencies of the different antibodies were in-
creasing. Also, higher levels of anti-CCP2, −CEP-1/Eno5-21
and -Fibß62-81b antibodies, respectively (three times above
the cutoff level) were associated with having HLA-SE al-
leles. These results could indicate that HLA-SE and/or
smoking is of importance for expansion of some of the
antibody specificities, but not for others. Thus, these anti-
bodies could have a more significant role in the pathogen-
esis of the development of the disease, whilst the presence
of the primary antibodies could result from less specific
responses.
Table 5 Gene-environment interaction of HLA-SE alleles and smoking in individuals prior to diagnosis of RA stratified
for the presence of autoantibodies against various citrullinated peptides compared with controls
All
HLA-SE Smoking Cases/controls OR (95% CI)
None Never 41/173 1.00 (Ref)
None Ever 78/162 2.03 (1.32–3.14)
Any Never 76/125 2.57 (1.65–4.00)





MI P = 0.35
Anti-CCP2 positive Anti-CCP2 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 10/173 1.00 (Ref) 31/173 1.00 (Ref)
None Ever 26/162 2.77 (1.30–5.94) 52/162 1.79 (1.09–2.94)
Any Never 24/125 3.32 (1.53–7.19) 52/125 2.32 (1.41–3.83)
Any Ever 66/92 12.41 (6.09–25.28) 84/92 5.10 (3.14–8.26)
Interaction
AP 0.59 (0.53–0.67) 0.39 (0.32–0.50)
RERI 7.31 (3.35–17.90) 1.98 (0.21–4.41)
SI 2.78 (1.49–5.19) 1.94 (1.03–3.66)
MI P = 0.53 P = 0.55
Anti-CCP-1/Fil307-324 positive Anti-CCP-1/Fil307-324 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 8/173 1.00 (Ref) 33/173 1.00 (Ref)
None Ever 18/162 2.40 (1.02–5.68) 60/162 1.94 (1.21–3.13)
Any Never 24/125 4.15 (1.81–9.55) 52/125 2.18 (1.33–3.57)
Any Ever 46/92 10.81 (4.90–23.88) 104/92 5.93 (3.72–9.45)
Interaction
AP 0.49 (0.40–0.60) 0.47 (0.41–0.56)
RERI 5.26 (0.52–15.71) 2.80 (1.02–5.55)
SI 2.15 (1.11–4.16) 2.32 (1.26–4.28)
MI P = 0.88 P = 0.30
Anti-Fibβ36-52 positive Anti-Fibβ36-52 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 10/173 1.00 (Ref) 31/173 1.00 (Ref)
None Ever 22/162 2.35 (1.08–5.11) 56/162 1.93 (1.18–3.14)
Any Never 22/125 3.04 (1.39–6.66) 54/125 2.41 (1.47–3.97)
Any Ever 53/92 9.97 (4.84–20.51) 97/92 5.88 (3.65–9.48)
Interaction
AP 0.56 (0.48–0.66) 0.43 (0.37–0.52)
RERI 5.57 (1.95–14.16) 2.54 (0.68–5.31)
SI 2.64 (1.31–5.34) 2.09 (1.15–3.77)
MI P = 0.50 P = 0.48
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Table 5 Gene-environment interaction of HLA-SE alleles and smoking in individuals prior to diagnosis of RA stratified
for the presence of autoantibodies against various citrullinated peptides compared with controls (Continued)
Anti-CEP-1/Eno5-21 positive Anti-CEP-1/Eno5-21 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 8/173 1.00 (Ref) 33/173 1.00 (Ref)
None Ever 20/162 2.67 (1.14–6.23) 58/162 1.88 (1.16–3.03)
Any Never 20/125 3.46 (1.47–8.11) 56/125 2.35 (1.44–3.83)
Any Ever 54/92 12.69 (5.79–27.81) 96/92 5.47 (3.42–8.75)
Interaction
AP 0.60 (0.52–0.69) 0.41 (0.34–0.51)
RERI 7.56 (3.14–20.18) 2.24 (0.47–4.77)
SI 2.83 (1.44–5.58) 2.00 (1.10–3.66)
MI P = 0.54 P = 0.51
Anti-Fibβ62-81a (72) positive Anti-Fibβ62-81a ( 72) negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 2/173 1.00 (Ref) 39/173 1.00 (Ref)
None Ever 6/162 3.20 (0.64–16.10) 72/162 1.97 (1.26–3.08)
Any Never 16/125 11.07 (2.50–49.02) 60/125 2.13 (1.34–3.39)
Any Ever 19/92 17.86 (4.07–78.38) 131/92 6.32 (4.08–9.79)
Interaction
AP 0.26 (0.02–0.48) 0.51 (0.46–0.59)
RERI 4.59 (–32.49−55.67) 3.21 (1.47–5.96)
SI 1.37 (0.65–2.90) 2.53 (1.42–4.52)
MI P = 0.45 P = 0.18
Anti-Fibβ62-81b (74) positive Anti-Fibβ62-81b (74) negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 3/173 1.00 (Ref) 37/173 1.00 (Ref)
None Ever 11/162 3.92 (1.07–14.29) 66/162 1.90 (1.21–3.00)
Any Never 11/125 5.07 (1.39–18.57) 65/125 2.43 (1.53–3.87)
Any Ever 32/92 20.06 (5.98–67.28) 109/92 5.54 (3.53–8.69)
Interaction
AP 0.60 (0.49–0.73) 0.40 (0.33–0.49)
RERI 12.07 (−0.05–53.96) 2.20 (0.47–4.63)
SI 2.72 (1.28–5.79) 1.94 (1.11–3.41)
MI P = 0.99 P = 0.57
Anti-Fibα580-600 positive Anti-Fibα580-600 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 4/173 1.00 (Ref) 36/173 1.00 (Ref)
None Ever 5/162 1.34 (0.35–5.06) 72/162 2.14 (1.36–3.36)
Any Never 10/125 3.46 (1.06–11.28) 66/125 2.54 (1.59–4.05)
Any Ever 29/92 4.70 (1.44–15.40) 131/92 6.84 (4.38–10.70)
Interaction
AP 0.72 (0.60–0.87) 0.46 (0.41–0.54)
RERI 9.84 (3.70–33.71) 3.17 (1.25–6.16)
SI 4.52 (1.37–14.87) 2.19 (1.30–3.67)
MI P = 0.17 P = 0.45
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Table 5 Gene-environment interaction of HLA-SE alleles and smoking in individuals prior to diagnosis of RA stratified
for the presence of autoantibodies against various citrullinated peptides compared with controls (Continued)
Anti-citC1359-369 positive Anti-citC1359-369 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 3/173 1.00 (Ref) 37/173 1.00 (Ref)
None Ever 11/162 3.92 (1.07–14.29) 66/162 1.90 (1.21–3.00)
Any Never 7/125 3.23 (0.82–12.73) 69/125 2.58 (1.63–4.09)
Any Ever 25/92 15.67 (4.61–53.29) 116/92 5.89 (3.77–9.23)
Interaction
AP 0.61 (0.46–0.77) 0.41 (0.35–0.49)
RERI 9.52 (−1.11–43.03) 2.41 (0.62–4.97)
SI 2.85 (1.16–6.98) 1.97 (1.14–3.39)
MI P = 0.79 P = 0.56
Anti-Vim60-75 positive Anti-Vim60-75 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 5/173 1.00 (Ref) 36/173 1.00 (Ref)
None Ever 6/162 1.28 (0.38–4.28) 72/162 2.14 (1.36–3.36)
Any Never 13/125 3.60 (1.25–10.35) 63/125 2.42 (1.51–3.87)
Any Ever 19/92 7.14 (2.58–19.76) 131/92 6.84 (4.38–10.70)
Interaction
AP 0.46 (0.24–0.70) 0.48 (0.42–0.55)
RERI 3.27 (−2.87–13.75) 3.28 (1.38–6.29)
SI 2.13 (0.72–6.36) 2.28 (1.34–3.88)
MI P = 0.55 P = 0.37
Anti-Fibα563-583 positive Anti-Fibα561-583 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 2/173 1.00 (Ref) 38/173 1.00 (Ref)
None Ever 10/162 5.34 (1.15–24.74) 68/162 1.86 (1.19-2-92)
Any Never 6/125 4.15 (0.82–20.91) 71/125 2.48 (1.58–3.91)
Any Ever 21/92 19.74 (4.53–86.07) 129/92 6.22 (4.01–9.64)
Interaction
AP 0.57 (0.39–0.76) 0.46 (0.41–0.54)
RERI 11.25 (−10.52–71.35) 2.87 (1.10–5.54)
SI 2.50 (1.05–5.95) 2.22 (1.29–3.85)
MI P = 0.90 P = 0.33
Anti-Vim2-17 positive Anti-Vim2-17 negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 1/173 1.00 (Ref) 40/173 1.00 (Ref)
None Ever 5/162 5.34 (0.62–46.20) 73/1162 1.95 (1.25–3.03)
Any Never 2/125 2.77 (0.25–30.87) 74/125 2.56 (1.64–4.01)
Any Ever 17/92 31.97 (4.19–244.04) 133/92 6.25 (4.05–9.66)
Interaction
AP 0.77 (0.54–0.99) 0.47 (0.42–0.54)
RERI 24.86 (−16.43–230.81) 2.74 (0.96–5.38)
SI 5.07 (1.42–18.16) 2.02 (1.23–3.54)
MI P = 0.56 P = 0.45
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Table 5 Gene-environment interaction of HLA-SE alleles and smoking in individuals prior to diagnosis of RA stratified
for the presence of autoantibodies against various citrullinated peptides compared with controls (Continued)
Any ACPA positive Any ACPA negative
HLA-SE Smoking Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None Never 23/173 1.00 (Ref) 16/173 1.00 (Ref)
None Ever 42/162 1.95 (1.12–3.39) 35/162 2.34 (1.25–4.38)
Any Never 52/125 3.13 (1.82–5.38) 25/125 2.16 (1.11–4.22)
Any Ever 88/92 7.19 (4.26–12.15) 53/92 6.23 (3.37–11.51)
Interaction
AP 0.43 (0.37–0.52) 0.44 (0.35–0.56)
RERI 3.11 (0.77–6.90) 2.73 (0.21–6.81)
SI 2.01 (1.15–3.52) 2.09 (1.02–4.29)
MI P = 0.65 P = 0.62
OR for the development of RA. Attributable proportion due to interaction (AP), relative excess due to interaction (RERI), synergy index (SI), and multiple interaction
(MI). HLA-SE= HLA shared epitope, OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide antibodies, anti CEP-1/Eno5-21= antibodies
against α-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen
(Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies
against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against
vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17, ACPA=anti-citrullinated peptide/protein antibody.
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smoking, and ACPA reactivities in sera obtained before
and after disease onset, respectively, we observed that
presence of HLA-SE was associated with a conversion
from seronegativity to seropositivity, occurring between
the time point of sampling before onset of disease and
the time point of sampling after the disease was devel-
oped. These data which indicate that HLA-SE is a major
factor in determining whether an ACPA-positive individ-
ual will develop RA, are in accordance with the recent
study of ACPA reactivities in twins with ACPA without
disease and twins with ACPA and RA, which showed
that twins with ACPA and RA were more frequently
HLA-SE positive compared with twins with ACPA with-
out RA [11]. The interaction analyses between HLA-SE
and smoking was particularly strong in individuals posi-
tive for antibodies against CCP2, Fibß36-52, CEP-1/
Eno5-21, and CCP-1/Fil307-324. An interaction was also
seen between HLA-SE and smoking irrespective of the
presence of any ACPA. Due to the resulting low number
of individuals in each subgroup when stratified for num-
ber of HLA-SE alleles, we were unable to analyse for
interaction based on the number of alleles.
The interaction between risk factors (HLA-SE alleles,
smoking, and ACPA) for disease progression is complex.
Since all of the cases included in this study were identi-
fied as having subsequently developed RA, it is difficult
to generalize the results of the relationships between the
factors. Interaction between HLA-SE and smoking pre-
dating disease onset has been shown in the study by
Karlson et al. [12], and also in patients with early RA
[7,21]. In the study by Karlson et al., the data was strati-
fied for rheumatoid factor seropositivity, reaching thehighest risk for heavy smokers with double copies of
HLA-SE (OR = 7.47, 95% CI: 2.77 to 20.11) [12]. In an-
other study by Arkema et al. [13] on 192 preclinical RA
cases, the frequency of positivity for any ACPA, includ-
ing 18 specificities, was 25% and 6% in controls. In that
study, the combination of HLA-SE and ACPA positivity
compared with those negative for HLA-SE and ACPA
yielded an OR of 33.3 (95% CI: 11.1 to 99.6), when
restricting the analyses to those with blood sampled less
than five years before the onset of disease [13]. Our data
showed a similar high OR for the combination of HLA-
SE and anti-CCP2 antibodies compared with being
HLA-SE and anti-CCP2 negative; although the present
data included all samples (median of 4.6 (IQR: 2.0 to 9.7)
years) irrespective of reducing the pre-dating time to less
than five years before onset of symptoms. The combina-
tions of the three most prevalent ACPA specificities
(CEP-1/Eno5-21, Fibß36-52, and CCP-1/Fil307-324) to-
gether with smoking and HLA-SE yielded a very high risk
for development of RA relative to the reference of being
negative for all three factors. The combination of the
three most frequently occurring ACPA together with
anti-CCP2 antibodies in ever -smokers with HLA-SE al-
leles gave the highest relative risk (OR = 105.7).
The estimated risks in some of the analyses should be
interpreted in the context of small sample sizes with
resulting large CIs. There are no clear difference in the
risk ratios between the ACPAs appearing with the high-
est frequencies (CEP-1/Eno5-21, Fibß36-52, and CCP-1/
Fil307-324), although each of them was clearly lower
when compared with anti-CCP2. Analysing a combin-
ation of the three yielded similar results compared with
that for anti-CCP2, and a very high relative risk was
Kokkonen et al. Arthritis Research & Therapy  (2015) 17:125 Page 14 of 15found when analysing the triple combination together
with anti-CCP2.
We are unable to confirm the results by Lundberg et al.,
who reported the most pronounced effects of reactivity to
CEP-1/Eno5-21 in early RA patients when compared with
that for Fibß36-52, CCP-1/Fil307-324, and Vim60-75 [9].
However, the present study represented individuals before
the onset of symptoms of RA, of whom all will develop
the disease, and it was not powered to compare whether
the achieved results differed from those in early RA
presented by Lundberg et al. [9]. Also, in the study by
Lundberg et al. the different ACPA specificities were ana-
lysed using ELISAs, without subtraction of the arginine
reactivities from the analyses [9].
Conclusions
From this study we can conclude that the interaction be-
tween risk factors for antibody development (HLA-SE
alleles, smoking, and ACPA) and disease progression is
complex. The development of increasing frequencies of
positivity of ACPA is related to the presence of HLA-SE
and being an ever-smoker. All three factors increase the
risk of disease development separately, and also by an
interaction between HLA-SE and smoking.
Additional file
Additional file 1: Table S1. Results of multiple regression analyses
(including antibodies, smoking, and HLA-SE, respectively) for development
of RA in individuals before the onset of any symptoms of disease.
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